Financials data is unavailable for this security.
View more
Year on year Dr Reddy's Laboratories Ltd grew revenues 13.54% from 245.88bn to 279.16bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 23.56% net income growth from 45.07bn to 55.68bn.
Gross margin | 59.06% |
---|---|
Net profit margin | 19.26% |
Operating margin | 23.58% |
Return on assets | 14.81% |
---|---|
Return on equity | 20.59% |
Return on investment | 19.71% |
More ▼
Cash flow in INRView more
In 2024, Dr Reddy's Laboratories Ltd increased its cash reserves by 22.98%, or 1.33bn. The company earned 45.43bn from its operations for a Cash Flow Margin of 16.27%. In addition the company used 40.28bn on investing activities and also paid 3.76bn in financing cash flows.
Cash flow per share | 5.07 |
---|---|
Price/Cash flow per share | 15.46 |
Book value per share | 21.15 |
---|---|
Tangible book value per share | 18.18 |
More ▼
Balance sheet in INRView more
Current ratio | 2.55 |
---|---|
Quick ratio | 1.90 |
Total debt/total equity | 0.1041 |
---|---|
Total debt/total capital | 0.0943 |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 29.38% and 23.32%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
Div yield(5 year avg) | 0.63% |
---|---|
Div growth rate (5 year) | 14.77% |
Payout ratio (TTM) | 12.03% |
EPS growth(5 years) | 24.18 |
---|---|
EPS (TTM) vs TTM 1 year ago | 17.48 |
More ▼